Clinical Trial Update: A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression [Phase 3]

View source ↗

Summary

Phase 3 trial comparing mirvetuximab soravtansine with investigator's choice chemotherapy in FRα-high, platinum-resistant epithelial ovarian, primary peritoneal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Fallopian Tube Cancer
• Peritoneal Cancer

Drugs mentioned

• Elahere (mirvetuximab soravtansine)

Snippet

Sponsor: AbbVie | Conditions: Epithelial Ovarian Cancer, Peritoneal Cancer | Phase 3 | Status: COMPLETED | Results posted: 2024-08-01